Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC-Reference-Cited by-同舟云学术

Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC

Published:2022-12 Issue: Volume:174 Page:36-44
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Salomone Fabio,Di Costanzo Fabrizio,Pecoraro Giovanna,Viscardi Giuseppe,Viggiano Angela,Napolitano Fabiana,Santaniello Antonio,Formisano Luigi,Bianco Roberto,Servetto Alberto^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Clinical endpoints in oncology - a primer;Delgado;Am. J. Cancer Res.,2021

2. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review;Savina;Crit. Rev. Oncol. Hematol.,2018

3. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents;Saad;Ann. Oncol.,2016

5. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline;Di Maio;Ann. Oncol.,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisão Sistemática de Estudos Observacionais sobre o uso de Erlotinibe e Gefitinibe no Tratamento do Câncer de Pulmão de Células Não Pequenas;Revista Brasileira de Cancerologia;2024-08-30

2. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS);HemaSphere;2024-05

4. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non–Small Cell Lung Cancer in ALTA-1L Trial;Value in Health;2024-02

5. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors;Cancers;2023-12-04